Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024)
Rapport Therapeutics (RAPP) reported Preferred Stock Liabilities of $145.3 million for Q1 2024, up 62.32% quarter-over-quarter from $89.5 million in Q4 2023.
Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Rapport Therapeutics (RAPP) has 2 years of Preferred Stock Liabilities data on file, last reported at $145.3 million in Q1 2024.
- Preferred Stock Liabilities for Q1 2024 came in at $145.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $145.3 million (changed N/A YoY), and the FY2023 annual result was $89.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $145.3 million in Q1 2024 per RAPP's latest filing, from $89.5 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $145.3 million in Q1 2024 and troughed at $89.5 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 145.25 Mn |
| Dec 31, 2023 | 89.49 Mn |
| Sep 30, 2023 | 89.49 Mn |
| Jun 30, 2023 | 89.49 Mn |